VET3-TGI: A potent combination of TGF-B inhibition and IL-12 expression derived from the VET™ platform

VET3-TGI builds on the VET™ platform by adding two therapeutic transgenes encoding IL-12 and a TGF-B inhibitor. TGF-B is known to be a potent suppressor of immune responses and is a major factor in determining the patient response to checkpoint therapies. Lack of specificity and poor tumor infiltration has so far prevented the clinical approval of TFG-B inhibitors in cancer treatment.

The combination of these two factors, alongside the systemic targeting of the tumor via the oncolytic viral platform, creates a powerful immunotherapeutic.